Table 1 Patient characteristics
Patients (ITT) | Patients | |||
|---|---|---|---|---|
Character | All ( n =29) | % | Evaluable ( n =23) | % |
Age (years) | ||||
Median (range) | 50 (34–66) | 48 (34–65) | ||
Menopausal status | ||||
Premenopausal | 1 | 1 | ||
Postmenopausal | 28 | 22 | ||
Hormonal receptor status | ||||
Positive | 18 | 62 | ||
Negative | 9 | 31 | ||
Unknown | 2 | 7 | ||
Prior treatment | ||||
Chemotherapy | 26 | 90 | 23 | 100 |
Anthracycline containing | 25 | 86 | 23 | |
Antihormonal therapy | 19 | 65 | 15 | 65 |
Radiotherapy | 17 | 59 | 15 | 65 |
Surgery | 14 | 48 | 12 | 52 |
Previous anthracycline | ||||
Adjuvant | 10 | 34 | 9 | 39 |
Palliative | 15 | 52 | 14 | 61 |
Prior chemotherapy lines | ||||
1 | 21 | 73 | 20 | 87 |
2 | 5 | 17 | 3 | 13 |
Sites of metastases | ||||
Bones | 20 | 69 | 16 | 70 |
Liver | 18 | 62 | 15 | 65 |
Lymph nodes | 16 | 55 | 12 | 52 |
Lungs | 10 | 35 | 6 | 26 |
Contralateral breast | 8 | 28 | 7 | 30 |
Skin | 5 | 17 | 4 | 17 |
Pleura | 4 | 14 | 3 | 13 |
Spleen | 1 | 3 | 1 | 3 |
No. of metastatic sites | ||||
Two or more | 26 | 90 | 20 | 87 |
Three more | 19 | 65 | 14 | 61 |
Four or more | 6 | 21 | 4 | 17 |
